mazindol has been researched along with Cognition Disorders in 2 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nikiforuk, A | 1 |
| GoĊembiowska, K | 1 |
| Popik, P | 1 |
| Wade, TV | 1 |
| Schneider, JS | 1 |
2 other studies available for mazindol and Cognition Disorders
| Article | Year |
|---|---|
Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Attention; Behavior, Animal; Brain Chemistry; C | 2010 |
Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Cognition Disorders; Corpus | 2001 |